API SUPPLIERS

API Suppliers

1

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

1

API REF. PRICE (USD / KG)

0

API Market Place

3

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

12

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Basilea Pharmaceutica

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Basilea Announces Approval of Antibiotic Zevtera® in China to Treat Community-Acquired Pneumonia and Hospital-Acquired Pneumonia

Details:

With the Drug Approval License Authorization, Zevtera is now approved in China for the treatment of adult patients with community-acquired pneumonia (CAP) and adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).

Lead Product(s): Ceftobiprole

Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Shenzhen China Resources Gosun Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 06, 2020

ASK
US